News and Press Releases
Press releases
Theralase® Therapeutic Laser Technology Enhances Cancer Destruction
Toronto, Ontario – November 27, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading b...
0Theralase® Anti-Cancer Vaccine Validated in Colorectal Cancer
Toronto, Ontario – November 22, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading b...
0Theralase® Demonstrates 24 Months Stability of Second Clinical Batch of Lead Anti-Cancer Drug
Toronto, Ontario – November 21, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading b...
0Theralase® Discovers New Anti-Cancer Vaccine
Toronto, Ontario – November 20, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading b...
0Theralase® Researcher Discovers Super Potent Anti-Cancer Drugs
Toronto, Ontario – November 13, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading b...
0Theralase® Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated
Toronto, Ontario – November 8, 2017 First Four Patients Treated with Company’s Anti-Cancer Treatment Achieve Pre-Defined Primary, Secondary and...
0Theralase® Anti-Cancer Drugs Independently Reviewed
Toronto, Ontario –October 31, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading bio...
0Theralase® Research to be Presented at International Conference
Toronto, Ontario –October 30, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading bio...
0Theralase® Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when Activated by X-Rays
Toronto, Ontario – September 25, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading ...
0Theralase Lead Anti-Cancer Drug Effective in the Destruction of Throat Cancer
Toronto, Ontario – September 19, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading ...
0in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.